Jason L Hornick
Overview
Explore the profile of Jason L Hornick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
453
Citations
13256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papke Jr D, Kovacs S, Odintsov I, Hornick J, Raskin K, Newman E, et al.
Am J Surg Pathol
. 2025 Mar;
PMID: 40077813
Giant cell tumors of bone are locally aggressive, frequently harbor H3F3A p.G34W mutations, and rarely undergo malignant transformation. The pathogenesis of malignant transformation remains incompletely characterized. Herein, we present 28...
2.
Wisdom A, Raut C, Haddox C, Hornick J, Jagannathan J, Painter C, et al.
Cancer
. 2025 Feb;
131(5):e35772.
PMID: 39980372
Soft tissue sarcomas are a rare group of mesenchymal malignancies, with greater than 100 histologic subtypes. Advancements in understanding these subtypes has enabled histology-tailored management. This primer describes the workup...
3.
Vernemmen A, van Kempen L, Aarts F, Zur Hausen A, Sciot R, Hornick J, et al.
Genes Chromosomes Cancer
. 2025 Feb;
64(2):e70035.
PMID: 39950323
USP8 fusions have recently been described in neoplasms in the provisional category of calcified chondroid mesenchymal neoplasm (CCMN). Here, we describe a cutaneous inflammatory myofibroblastic tumor (IMT) on the upper...
4.
5.
Pimenta E, Garza A, Camp S, Park J, Hoffman S, Valderrabano L, et al.
bioRxiv
. 2025 Feb;
PMID: 39896505
Sarcomas are rare connective tissue cancers thought to arise from aberrant mesenchymal stem cell (MSC) differentiation. Liposarcoma (LPS) holds valuable insights into dysfunctional differentiation given its well- and dedifferentiated histologic...
6.
Odintsov I, Papke D, George S, Padera R, Hornick J, Siegmund S
Clin Cancer Res
. 2025 Jan;
PMID: 39820259
Purpose: Cardiac angiosarcoma (CAS) is a rare, aggressive malignancy with limited treatment options. Both sporadic and familial cases occur, with recent links to germline POT1 mutations. The genomic landscape of...
7.
Abebe K, Orholt M, Bak E, Larsen A, Wagenblast A, Schmidt G, et al.
J Am Acad Dermatol
. 2024 Oct;
92(3):569-572.
PMID: 39476978
No abstract available.
8.
Haddox C, Hornick J, Roland C, Baldini E, Keedy V, Riedel R
Cancer Treat Rev
. 2024 Oct;
131:102846.
PMID: 39454547
Dedifferentiated liposarcoma (DDLPS) is a malignant mesenchymal neoplasm in desperate need of novel therapeutic approaches. Often occurring in conjunction with well-differentiated liposarcoma (WDLPS), DDLPS can behave more aggressively and exhibits...
9.
Fischer G, Mahadevan N, Hornick J, Fletcher C, Russell-Goldman E
Mod Pathol
. 2024 Sep;
37(12):100626.
PMID: 39332711
Undifferentiated melanoma, defined as melanoma that has lost all usual phenotypic and immunohistochemical characteristics of conventional melanoma, can pose significant diagnostic challenges. Molecular studies have advanced our understanding of undifferentiated...
10.
DeSimone M, Odintsov I, Tsai H, Dickson B, Alomari A, Hornick J, et al.
Am J Surg Pathol
. 2024 Sep;
PMID: 39329254
Anaplastic lymphoma kinase (ALK) rearrangements drive most examples of epithelioid fibrous histiocytoma (EFH) and have been reported in an emerging family of receptor tyrosine kinase (RTK) fusion-positive mesenchymal neoplasms, including...